ORIC Pharmaceuticals, Inc. (ORIC) Financial Statements
Free cash flow over the same period: -$112.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ORICORIC Pharmaceuticals, Inc.Follow ORIC — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 35.9 | 56.9 | 61.7 | 85.2 | 114.1 | 109.8 | 122.4 | |
| Operating income | -74.2 | -78.9 | -91.8 | -110.8 | -142.9 | -143.0 | -156.1 | |
| Pre-tax income | -73.7 | -78.7 | -89.1 | -100.7 | -127.8 | -129.5 | -140.4 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -73.7 | -78.7 | -89.1 | -100.7 | -127.8 | -129.5 | -140.4 | |
| Diluted EPS ($) | -3.36 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.29 | |
| Diluted shares (mn) | — | — | 39.7 | 51.5 | 69.7 | 87.8 | — |
USD millions · SEC XBRL
ORIC Pharmaceuticals, Inc. — questions
- What is ORIC Pharmaceuticals, Inc.'s net income?
- -$140.4M over the twelve months to 2026-06-30.
- What is ORIC Pharmaceuticals, Inc.'s free cash flow?
- -$112.3M over the twelve months to 2026-06-30.
- What are ORIC Pharmaceuticals, Inc.'s diluted earnings per share?
- $-1.29 over the twelve months to 2026-06-30.
Every figure on this page comes from ORIC Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.